http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers
-
Agenus Reports Second Quarter 2023 Results
-
Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023
-
Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update
-
Agenus (AGEN) Expands Executive Team
-
Agenus Expands Executive Leadership Team
-
ESMO GI Data: Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer
-
Agenus (AGEN) Presents Positive Efficacy and Safety Outcomes for AGEN2373
-
Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO
-
Agenus Announces Virtual Annual Shareholders Meeting
-
Agenus to Participate in Jefferies Healthcare Conference
-
Agenus Provides Corporate Update and First Quarter 2023 Financial Results
-
Agenus to Present at the American Society of Clinical Oncology 2023 Annual Meeting
-
Agenus to Provide Corporate Update and First Quarter 2023 Financial Report
-
Agenus to Participate in May Investor Conferences
-
Agenus (AGEN) Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer
-
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer
-
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
-
Agenus' (AGEN) Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer
-
Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer
-
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
-
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
-
Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement
-
Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement
-
Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
-
Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
-
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report
-
Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer
-
Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer
-
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report
-
Agenus to Participate in February Investor Conferences
-
Agenus to Participate in February Investor Conferences
-
Agenus (AGEN) Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination
-
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
-
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
-
Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference
-
Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference
-
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
-
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
-
Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma
-
Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma
-
Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
-
Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
-
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers
-
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers
-
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report
-
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report
-
Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report
-
Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report
-
Agenus (AGEN) Reports GSK's RSV Vaccine Candidate Showed 94.1% Reduction and 82.6% Overall Efficacy Against RSV
